Latest News

Date Title Topic
11 Sep 2017 ESMO 2017: Adjuvant Dabrafenib Plus Trametinib Significantly Lowers Risk of Death in Stage III BRAF V600–Mutated Melanoma Melanoma and other skin tumours - Anticancer agents & Biologic therapy
11 Sep 2017 ESMO 2017: Nivolumab Bests Ipilimumab as Adjuvant Therapy in Resected Melanoma Melanoma and other skin tumours - Cancer Immunology and Immunotherapy
11 Sep 2017 ESMO 2017: BRIM8 Data Shows Benefit with Adjuvant Vemurafenib in Resected BRAFV600 Positive Melanoma Melanoma and other skin tumours - Anticancer agents & Biologic therapy
11 Sep 2017 ESMO 2017 Press Release: Adjuvant Nivolumab Superior to Ipilimumab in Surgically Resected Stage III/IV Melanoma Melanoma and other skin tumours
11 Sep 2017 ESMO 2017 Press Release: KEYNOTE-040 Evaluates Pembrolizumab in Head and Neck Cancer Head and neck cancers
11 Sep 2017 ESMO 2017 Press Release: Combination Targeted Adjuvant Therapy Doubles Relapse-free Survival in Stage III Melanoma Melanoma and other skin tumours
11 Sep 2017 ESMO 2017 Press Release: Debate on Duration of Colon Cancer Adjuvant Chemotherapy Takes Centre Stage at ESMO 2017 Gastrointestinal cancers
Thanks to all!
10 Sep 2017 ESMO 2017: Photo Reportage
10 Sep 2017 ESMO 2017: Pembrolizumab Continues to Show Greater Benefit over Chemotherapy in Recurrent, Advanced Urothelial Carcinoma Genitourinary cancers - Cancer Immunology and Immunotherapy
10 Sep 2017 ESMO 2017: Ramucirumab Improves PFS in Patients with Platinum Refractory Advanced Urothelial Carcinoma Genitourinary cancers - Anticancer agents & Biologic therapy
10 Sep 2017 ESMO 2017: Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment for Advanced or Metastatic RCC Genitourinary cancers - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
10 Sep 2017 ESMO 2017: Combined Abemaciclib with NSAI Show Significant Clinical Benefit as Initial Treatment for Patients with HR-positive/HER2-negative ABC at Interim Analysis Breast cancer - Anticancer agents & Biologic therapy
10 Sep 2017 ESMO 2017: Biosimilar Rituximab Shows Equivalent Efficacy to Reference Rituximab in Previously Untreated Advanced Follicular Lymphoma Haematologic malignancies - Anticancer agents & Biologic therapy
10 Sep 2017 ESMO 2017 Media Alert: ESMO 2017 Shows Support for World Cancer Research Day